Search Results - "Goldblum, O.M."

Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy by Strober, B.E., Poulin, Y., Teller, C., Wang, Y., Williams, D.A., Goldblum, O.M.

“…Background Psoriasis treatment can lower levels of the inflammatory biomarker C‐reactive protein (CRP). Objective Evaluate CRP changes in patients with chronic…”
Get full text

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH by Poulin, Y., Crowley, J.J., Langley, R.G., Unnebrink, K., Goldblum, O.M., Valdecantos, W.C.

“…Background The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that…”
Get full text